Cerus Corporation (CERS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cerus Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.20 $ — 48% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 104.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.02 | -0.02 – -0.02 | 231 | 75.0% | 1 |
| 12/31/2027 | 0.03 | 0.03 – 0.03 | 264 | 250.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.01 | – | 51 | 8.60 | -5.00 | 5 | 4 |
| 2025: Q1 | -0.04 | – | 43 | 12.70 | -17.80 | -1 | -1 |
| 2025: Q2 | -0.03 | – | 52 | 16.30 | -10.90 | -2 | -3 |
| 2025: Q3 | 0.00 | – | 53 | 14.50 | 0.00 | 2 | 0 |
| 2025: Q4 | -0.01 | – | 58 | 13.70 | -3.80 | 6 | 5 |
| 2026: Q1 | -0.01 | – | 54 | 24.30 | -3.10 | -3 | -3 |
| 2026: Q2 | -0.01 | 66.70 | 57 | 9.50 | -5.10 | -3 | -4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 37 | -61 | -63 | -0.62 | -54 | 58 | 103 |
| 2017 | 44 | -58 | -61 | -0.56 | -52 | 39 | 98 |
| 2018 | 61 | -55 | -58 | -0.44 | -31 | 85 | 163 |
| 2019 | 75 | -66 | -71 | -0.51 | -66 | 57 | 166 |
| 2020 | 92 | -58 | -60 | -0.37 | -42 | 104 | 221 |
| 2021 | 131 | -49 | -54 | -0.32 | -34 | 85 | 238 |
| 2022 | 162 | -34 | -43 | -0.24 | -26 | 68 | 218 |
| 2023 | 156 | -30 | -37 | -0.21 | -43 | 53 | 198 |
| 2024 | 180 | -14 | -21 | -0.11 | 11 | 56 | 201 |
| 2025 | 206 | -36 | -16 | -0.08 | 11 | 64 | 222 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
| Employees | 261 |
|---|---|
| Headquarters | Concord, CA |
| Address | 1220 Concord Avenue, 94520 Concord, United States |
| Phone | 925 288 6000 |
| Website | cerus.com |
| IPO Date | 30. Jan 1997 |
| ISIN | US1570851014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| William M. Greenman | Executive Chairman of the Board | 1967 |
| Vivek K. Jayaraman | CEO, President & Director | 1975 |
| Kevin D. Green CPA | VP of Finance & CFO | 1972 |
| Chrystal N. Jensen J.D. | Chief Legal Officer, General Counsel & Secretary | 1971 |
| Richard J. Benjamin MBChB, Ph.D. | Chief Medical Officer | 1960 |
| Timothy J. Lee | Head of Investor Relation | – |
| Lainie Corten | Vice President of Global Marketing | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jul 2026 | Jayaraman Vivek K | Chief Executive Officer | Sell | 16,666 | 3.16 | 52,665 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.